Fresenius Invests in BioIntellisense AI Platform

“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.

Read the full article » | Posted 09/11/2019

Related Articles